GIOSTAR's founder, Dr. Anand Srivastava, is listed on PubMed as an author of nine peer-reviewed papers with an affiliation at the Global Institute of Stem Cell Therapy and Research, the institute behind GIOSTAR's research ([1] through [9]). This count uses the affiliation on each author line. The papers are reviews and small reports ([1] through [9]). They are not clinical trials ([1] through [9]), and nothing here describes what a GIOSTAR treatment will do for a reader. Full details of the founder are on the founder page.
The field's shared definitions
Researchers in this area use the term mesenchymal stem cells, which a 2006 consensus statement defined by three laboratory criteria: plastic adherence in culture, a set of surface markers, and the ability to form bone, cartilage and fat cells [10]. A 2017 article argued the name should change, because these cells appear to act mainly through the signals they release [11]. The papers below use the term in that sense.
The nine papers
Reviews. Each of these is a narrative review ([2], [3], [5], [6], [7], [8], [9]), which summarizes published work without a formal pooled analysis.
- 2019, overview of stem cells in tissue regeneration. Covers the types of stem cells and their use in regenerative medicine [2].
- 2020, stem cell interventions for advanced liver disease. Reviews the clinical studies and argues that controlled trials with long-term follow-up are still needed [3].
- 2020, stem cell therapy for vitiligo. Reviews the proposed immune and oxidative mechanisms and the reported results of cell-derived treatments [5].
- 2020, stem cell therapy for inflammatory bowel disease. Reviews the limits of current drugs and the stem cell approaches under study [6].
- 2021, stem cell therapy in COVID-19. Reviews the immune-modulating rationale for cell therapy in COVID-19 pneumonia [7].
- 2024, stem cell therapy and diabetes. Reviews the inflammation and cell damage behind diabetes and the stem cell approaches proposed for them [8].
- 2024, stem cell therapy for osteoarthritis and rheumatoid arthritis. Reviews the inflammatory processes of both conditions and the stem cell approaches under study [9].
Case report of one. One paper describes a single patient with scalp psoriasis treated with conditioned medium from mesenchymal stem cells [1]. The reported severity score fell from 28 to 0 over one month [1]. One patient cannot show what happens in others [1].
Animal study. One paper tested a polyherbal Ayurvedic formulation, Dhanwantaram kashayam, in rats with diabetes [4]. It restored antioxidant enzyme activity and lowered lipid levels in those rats [4]. The paper describes the formulation as a preparation from plants [4]. The paper suggests it could be developed as a dietary supplement that might ease diabetes complications [4].
What the papers do and do not show
The nine papers are reviews, one case report of a single patient, and one animal study ([1] through [9]). None of them is a trial that tests a treatment in a group of people with a control group, and none is evidence that a treatment works for a condition named in its title ([1] through [9]). ClinicalTrials.gov lists one phase 2 study sponsored by the same institute, NCT06789302, which was not yet recruiting when checked, has an estimated enrollment of 120, and has no results posted [13].
How to check any author's publications
Search the founder's page, which lists the same papers, and compare them with the list above. Each paper's PubMed record is linked from that page. Registered trials for the same field are listed on ClinicalTrials.gov. The other guides cover stem cell research and the knee, peripheral neuropathy, systemic infusion and aging.
Regulatory Status
A 2026 review of FDA regulation of biologics examines how that oversight applies to stem cell products [12]. Our stem cell therapy is not approved by the FDA.
